CoChat

Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study

Open access
Suarez, Maria Gabriela, Stack, Madeleine, Hinojosa-Amaya, Jose Miguel, Mitchell, Michael D, Varlamov, Elena V, Yedinak, Chris G, Cetas, Justin S, Sheppard, Brett, Fleseriu, Maria · 2020 · Journal of the Endocrine Society
Cited by 68

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background: The risk of Cushing syndrome (CS) patients experiencing a thrombotic event (TE) is significantly higher (odds ratio; OR 18%) than that of the general population. However, there are currently no anticoagulation guidelines. Methods: A retrospective, single-center, longitudinal study of patients undergoing all types of treatment—surgical (pituitary, unilateral, and bilateral adrenalectomy) and medical treatment—was undertaken. TEs were recorded at any point up until last patient follow-up; myocardial infarction (MI), deep venous thrombosis (DVT), and pulmonary embolism (PE) or stroke. Patients’ doses and complications of anticoagulation were recorded. Results: Included were 208 patients; a total of 165 (79.3%) were women, and mean age at presentation was 44 ± 14.7 years. Thirty-nine (18.2%) patients had a TE; extremity DVT (38%), cerebrovascular accident (27%), MI (21%), and PE (14%). Of 56 TEs, 27 (48%) were arterial and 29 (52%) were venous. Patients who underwent bilateral adrenalectomy (BLA) had an odds ratio of 3.74 (95% CI 1.69-8.27) of developing a TE. Of patients with TEs, 40.5% experienced the event within the first 60 days after surgery. Baseline 24-hour urinary free cortisol levels did not differ in patients with or without TE after BLA. Of 197 patients who underwent surgery, 50 (25.38%) received anticoagulation after surgery, with 2% having bleeding complications. Conclusions: The risk of TEs in patients with CS was approximately 20%. Many patients had more than 1 event, with higher risk 30 to 60 days postoperatively. The optimal prophylactic anticoagulation duration is unknown, but most likely needs to continue up to 60 days postoperatively, particularly after BLA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jendso/bvz033

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 35

  1. Clayton, 2011, Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature, J Clin Endocrinol Metab., 96, 632, 10.1210/jc.2010-1942 · DOI · Paper page
  2. Pivonello, 2016, Complications of Cushing’s syndrome: state of the art, Lancet Diabetes Endocrinol., 4, 611, 10.1016/S2213-8587(16)00086-3 · DOI · Paper page
  3. Johannesdottir, 2013, Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study, JAMA Intern Med., 173, 743, 10.1001/jamainternmed.2013.122 · DOI · Paper page
  4. Świątkowska-Stodulska, 2015, Activity of selected coagulation factors in overt and subclinical hypercortisolism, Endocr J., 62, 687, 10.1507/endocrj.EJ14-0539 · DOI
  5. Fatti, 2000, Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome, J Endocrinol Invest., 23, 145, 10.1007/BF03343697 · DOI
  6. Jenkins, 2012, Elevated factor VIII levels and risk of venous thrombosis, Br J Haematol., 157, 653, 10.1111/j.1365-2141.2012.09134.x · DOI · Paper page
  7. Cavusoglu, 2011, Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome, Am J Med., 124, 724, 10.1016/j.amjmed.2011.02.040 · DOI
  8. Pecori Giraldi, 2011, Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing’s disease, Br J Clin Pharmacol., 71, 132, 10.1111/j.1365-2125.2010.03812.x · DOI
  9. van der Pas, 2012, The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy, J Clin Endocrinol Metab., 97, 1303, 10.1210/jc.2011-2753 · DOI · Paper page
  10. Karamouzis, 2015, Enhanced oxidative stress and platelet activation in patients with Cushing’s syndrome, Clin Endocrinol (Oxf)., 82, 517, 10.1111/cen.12524 · DOI
  11. Greenhill, 2016, Pituitary disease: inflammation in patients with Cushing disease, Nat Rev Endocrinol., 12, 687, 10.1038/nrendo.2016.170 · DOI
  12. Wagner, 2018, Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing’s syndrome: a systematic meta-analysis, Front Endocrinol (Lausanne)., 9, 805, 10.3389/fendo.2018.00805 · DOI · Paper page
  13. Koutroumpi, 2013, Venous thromboembolism in patients with Cushing’s syndrome: need of a careful investigation of the prothrombotic risk profile, Pituitary., 16, 175, 10.1007/s11102-012-0398-4 · DOI
  14. Semple, 1999, Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing’s disease, J Neurosurg., 91, 175, 10.3171/jns.1999.91.2.0175 · DOI · Paper page
  15. Rees, 2002, Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission, Clin Endocrinol (Oxf)., 56, 541, 10.1046/j.1365-2265.2002.01511.x · DOI · Paper page
  16. Flevas, 2018, Thromboembolism prophylaxis in orthopaedics: an update, EFORT Open Rev., 3, 136, 10.1302/2058-5241.3.170018 · DOI · Paper page
  17. Bjørnarå, 2006, Frequency and timing of clinical venous thromboembolism after major joint surgery, J Bone Joint Surg Br., 88, 386, 10.1302/0301-620X.88B3.17207 · DOI
  18. Lambert, 2013, Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients, J Clin Endocrinol Metab., 98, 1022, 10.1210/jc.2012-2893 · DOI · Paper page
  19. Petersenn, 2014, High variability in baseline urinary free cortisol values in patients with Cushing’s disease, Clin Endocrinol (Oxf)., 80, 261, 10.1111/cen.12259 · DOI · Paper page
  20. van Haalen, 2015, Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis, Eur J Endocrinol., 172, R143, 10.1530/EJE-14-0556 · DOI · Paper page
  21. Kastelan, 2013, Hypercoagulable state in Cushing’s syndrome is reversible following remission, Clin Endocrinol (Oxf)., 78, 102, 10.1111/j.1365-2265.2012.04479.x · DOI
  22. Guarnotta, 2017, The degree of urinary hypercortisolism is not correlated with the severity of Cushing’s syndrome, Endocrine., 55, 564, 10.1007/s12020-016-0914-9 · DOI
  23. Valassi, 2018, Preoperative medical treatment in Cushing’s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN, Eur J Endocrinol., 178, 399, 10.1530/EJE-17-0997 · DOI · Paper page
  24. Coelho, 2015, Adverse effects of glucocorticoids: coagulopathy, Eur J Endocrinol., 173, M11, 10.1530/EJE-15-0198 · DOI
  25. Small, 1983, Thromboembolic complications in Cushing’s syndrome, Clin Endocrinol (Oxf)., 19, 503, 10.1111/j.1365-2265.1983.tb00025.x · DOI
  26. Babic, 2019, Is VTE prophylaxis necessary on discharge for patients undergoing adrenalectomy for Cushing syndrome?, J Endocr Soc., 3, 304, 10.1210/js.2018-00278 · DOI
  27. van der Pas, 2013, Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment, Clin Endocrinol (Oxf)., 78, 481, 10.1111/cen.12094 · DOI · Paper page
  28. Boscaro, 2002, Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome, J Clin Endocrinol Metab., 87, 3662
  29. Barbot, 2015, Perioperative thromboprophylaxis in Cushing’s disease: what we did and what we are doing?, Pituitary., 18, 487, 10.1007/s11102-014-0600-y · DOI
  30. Smith, 2015, Defensive medicine in neurosurgery: does state-level liability risk matter?, Neurosurgery., 76, 105, 10.1227/NEU.0000000000000576 · DOI
  31. Lang, 2015, The serum- & glucocorticoid-inducible kinase in the regulation of platelet function, Acta Physiol (Oxf)., 213, 181, 10.1111/apha.12334 · DOI
  32. Casonato, 1999, Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome, Blood Coagul Fibrinolysis., 10, 145, 10.1097/00001721-199904000-00006 · DOI · Paper page
  33. Manetti, 2010, Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery, Eur J Endocrinol., 163, 783, 10.1530/EJE-10-0583 · DOI · Paper page
  34. Zilio, 2016, A venous thromboembolism risk assessment model for patients with Cushing’s syndrome, Endocrine., 52, 322, 10.1007/s12020-015-0665-z · DOI
  35. Pace, 2017, European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma, Lancet Oncol., 18, e330, 10.1016/S1470-2045(17)30345-5 · DOI · Paper page

Cited by

Metadata

Authors
Suarez, M. G., Stack, M., Hinojosa-Amaya, J. M., Mitchell, M. D., Varlamov, E. V., Yedinak, C. G., Cetas, J. S., Sheppard, B., & Fleseriu, M.
Venue
Journal of the Endocrine Society
Published
2019-12-15
Volume
4
Issue
2
Pages
bvz033-bvz033
ISSN
2472-1972 (ISSN-L)
OpenAlex
W2996524239
Cited by
68
References
10
FWCI
4.65
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.